title: The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.
abstract: A clinical trial employing an immunotherapeutic approach based on the use of a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes carrying tumour-associated antigens is planned in advanced ovarian cancer in conjunction with conventional first line chemotherapy. Most patients with ovarian cancer present with advanced disease and despite high initial response rate to chemotherapy the majority will relapse within 2 years with poor overall survival. Tumour antigen-specific T cells are naturally occurring in ovarian cancer patients and T cell infiltration of the tumour is highly prognostic. Novel immunotherapy to expand and activate tumour antigen-specific T cells combined with adjuvant treatment to overcome tumour-induced immunosuppression is considered to be therapeutically beneficial. The rationale for adopting such a combined approach is discussed here.
authors.affiliation: Velindre Hospital, Whitchurch, Cardiff and Cardiff University School of Medicine, Cardiff, UK. malcolm.adams@velindre-tr.wales.nhs.uk
authors.forename: M
authors.initials: M
authors.lastname: Adams
authors.forename: H
authors.initials: H
authors.lastname: Navabi
authors.forename: D
authors.initials: D
authors.lastname: Croston
authors.forename: S
authors.initials: S
authors.lastname: Coleman
authors.forename: Z
authors.initials: Z
authors.lastname: Tabi
authors.forename: A
authors.initials: A
authors.lastname: Clayton
authors.forename: B
authors.initials: B
authors.lastname: Jasani
authors.forename: M D
authors.initials: MD
authors.lastname: Mason
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic / Q000379:methods; D003131:Combined Modality Therapy; D018899:CpG Islands; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008562:Membrane Glycoproteins / Q000819:agonists*; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy*; D011070:Poly I-C / Q000627:therapeutic use; D011956:Receptors, Cell Surface / Q000819:agonists*; D051196:Toll-Like Receptor 3; D051193:Toll-Like Receptors; D019444:Vaccines, DNA / Q000627:therapeutic use
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D008562:Membrane Glycoproteins; D011956:Receptors, Cell Surface; C495344:TLR3 protein, human; D051196:Toll-Like Receptor 3; D051193:Toll-Like Receptors; D019444:Vaccines, DNA; D011070:Poly I-C